About AC Immune
AC Immune is a publicly listed company based in Lausanne (Switzerland) founded in 2003. It operates as an antibodies, small molecules, and vaccines are developed for neurodegenerative diseases. AC Immune has raised $119.82 million across 9 funding rounds from investors including Lilly, The Michael J. Fox Foundation and BVF Partners. The company has 172 employees. Its chief executive is Andrea Pfeifer. Its website acimmune.com draws about 11 thousand monthly visits. AC Immune offers products and services including Active Immunotherapies, Morphomer Platform, and Supraantigen Platform. Its focus areas include Life Sciences, Neurology, Drugs and Neurodegenerative. Its legal entity is AC Immune SA. Its competitors include BeiGene, Vir Biotechnology, Cidara Therapeutics, BioNTech and Decibel Therapeutics and 3 more; 6 of its 8 listed competitors have raised funding.
Company details
AC Immune was founded in 2003 in Lausanne, Switzerland, within the biotechnology sector. Focus is placed on developing antibodies, small molecules, and vaccines targeting Alzheimers disease, Parkinsons, Down syndrome, and glaucoma. A diversified pipeline is maintained, supported by technology platforms such as SupraAntigen for diagnostics and biologics, and Morphomer for small molecule drugs. Operations emphasize neurodegenerative disorders through research and therapeutic innovation.
- Headquarters Lausanne, Switzerland
- Employees 172
- Stage Public
- SectorsHealthcare
- Website category Health · Biotechnology and Pharmaceuticals
- Website acimmune.com
- Social LinkedIn X
- Legal Name Ac Immune Sa
- Annual Revenue$4.3 M (USD)-86.13as on Dec 31, 2025
- Net Profit-$84.83 M (USD)-46.72as on Dec 31, 2025
- EBITDA-$80.02 M (USD)-39.94as on Dec 31, 2025
- Total Equity Funding$119.82M (USD)
in 9 rounds
- InvestorsLilly
& 4 more
- Employee Count172
Products & Services of AC Immune
AC Immune offers a comprehensive portfolio of products and services, including Active Immunotherapies, Morphomer Platform, and Supraantigen Platform.
Develops treatments targeting proteins in neurodegenerative diseases.
Facilitates creation of small molecule drugs for disease treatment.
Enables development of biologics for neurodegenerative therapies.
Funding Insights of AC Immune
AC Immune has successfully raised a total of $119.82M across 9 strategic funding rounds. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $119.82M
- Total Rounds 9
- First Round $2.21M
(Jul 2003)
- Investors Count 5
All 9 funding rounds of AC Immune with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Dec 2023 | – | Post-IPO | – | – | |
| Sep 2022 | $500,000 | Grant | – | – | |
| Sep 2019 | – | Grant | – | – | |
| Dec 2018 | $50M | Post-IPO | – | – | |
| May 2016 | $43.5M | Series E | – | – | – |
| Jan 2014 | $21.98M | Series D | – | – | – |
| Jan 2009 | $34.66M | Series C | – | – | – |
| May 2005 | $17.47M | Series B | – | – | – |
| Jul 2003 | $2.21M | Series A | – | – | – |
5 investors in total: 5 institutional.
Investors in AC Immune
AC Immune has secured backing from 5 investors, including venture fund and institutional investors. Prominent investors backing the company include Lilly, The Michael J. Fox Foundation and BVF Partners.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
US private equity investments are managed by BVF Partners. | – | bvflp.com | San Francisco, United States | |
Venture capital firm focused on multiple sectors | – | aviditypartners.tcc.mode | Dallas, United States | |
Operates as an employee-owned hedge fund focused on long/short equity strategies. | 2007 | redmilegroup.com | San Francisco, United States | |
Research for Parkinson's disease is funded by the foundation. | 2000 | michaeljfox.org | New York, United States | |
Traditional pharmaceutical medicines are developed for multiple health fields. | 1876 | lilly.com | United States |
Investor details for AC Immune
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of AC Immune
78 people are tracked at AC Immune (16 in leadership, 20 in board & advisors, 42 in team); the tracked headcount is 172.
| Name | Role | Group |
|---|---|---|
Andrea Pfeifer | CEO | Leadership |
Madiha Derouazi | Chief Scientific Officer | Leadership |
Olivier Sol | VP & Head, Clinical Development | Leadership |
Piergiorgio Donati | Chief Technical Operations Officer | Leadership |
Julien Rongère | VP, Regulatory Affairs & Quality Assurance | Leadership |
Howard Donovan | Chief Human Resources Officer | Leadership |
Christopher Roberts | Interim Chief Financial Officer | Leadership |
Valerie Bigouret-Hliva | Head Of Clinical Operations | Leadership |
Marie Laurencin | Head Of Clinical Operations | Leadership |
Christopher R. | Chief Financial Officer | Leadership |
Anke Post | Chief Medical Officer | Leadership |
Alain Pirlot | Executive Assistant To The CSO And The CFO | Leadership |
Maria Pilar Lopez Deber | Head Of Analytical Development And Quality Control | Leadership |
Gary Waanders | Head Of Investor Relations And Communications | Leadership |
Gautam Maitra | Head Of Regulatory Affairs | Leadership |
Chantal Bazenet | VP Of Strategic Portfolio And Program Management | Leadership |
Fred Van Leuven | Scientific Advisor | Board & advisors |
Emmanuelle M. Voisin Lestringant | Scientific Advisor | Board & advisors |
Douglas E. Williams | Chairman | Board & advisors |
Carl June | Director | Board & advisors |
58 more people are available in the full profile.
Complete people profiles for AC Immune
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
IPO & Listings of AC Immune
AC Immune is a publicly listed company on the NASDAQ with ticker symbol ACIU in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
- IPO date23 Sep 2016
- Listed onNASDAQ: ACIU
- Listed entityAC Immune SA
- Exchange sectorHealth technology
- ISINCH0329023102
- Share price$2.40 (-2.04% on the day) · 2026-10-13
- Market capitalisation$244.3M
- EPS (diluted, trailing year)$-0.56
- Volume (last session)194,919
Financials of AC Immune
| Year | Revenue | Net income | EBITDA |
|---|---|---|---|
| 2025 | $4.3M | -$84.8M | -$80.0M |
| 2024 | $31.0M | -$57.8M | -$57.2M |
| 2023 | $16.5M | -$60.4M | -$58.9M |
| 2022 | $4.1M | -$74.1M | -$73.1M |
| 2021 | – | -$79.8M | -$85.1M |
Detailed financial statements for AC Immune
Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.
- Statement rows
- Financial ratios
- Five-year trends
- Downloads
Verified entity values are shown only after access is granted.
Timeline of AC Immune
4 dated milestones of AC Immune across 20 years, from founding to its latest funding, stage changes and deals.
- Founded AC Immune is founded.
- Funding First funding round of $2.2M.
- IPO Lists on the stock exchange (IPO).
- Funding Latest funding round, Post-IPO,.
Competitors of AC Immune
AC Immune has 8 listed competitors in our database, 6 of them funded. They include BeiGene, Vir Biotechnology, Cidara Therapeutics, BioNTech and Decibel Therapeutics, among others.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| beigene.com | 2010 | Cambridge, United States | $172M | 1,090 | Targeted and immune-oncology drugs for cancer treatment are developed. | |
| vir.bio | 2017 | San Francisco, United States | $216M | 417 | Developer of therapeutics for the treatment of infectious diseases | |
| cidara.com | 2013 | San Diego, United States | $78.35M | 90 | Novel anti-infectives for bacterial and fungal infections are developed. | |
| biontech.com | 2008 | Mainz, Germany | $805.99M | 4,530 | Immunotherapeutics for cancer and other diseases are developed. | |
| decibeltx.com | 2015 | Cambridge, United States | $169.53M | 62 | Medicines are developed to protect, repair, and restore hearing capacity. | |
| seruminstitute.com | 1966 | Pune, India | – | 6,617 | Vaccines and immuno-biological drugs for infectious diseases are manufactured. | |
| sorrentotherapeutics.com | 1989 | San Diego, United States | – | 949 | Immuno therapeutics for cancer, inflammation, and autoimmune diseases are developed. | |
| imaginab.com | 2007 | Los Angeles, United States | $59.64M | 17 | ImaginAb is focused on developing advanced immuno-oncology imaging technologies. |
Detailed competitors of AC Immune
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of AC Immune
The website of AC Immune (acimmune.com) receives about 11.3K visits a month and ranks #1,671,085 among all websites worldwide, #2,248 in Biotechnology and Pharmaceuticals.
- Monthly visits11.3K
▼ 17.1% vs previous month
- Unique visitors5.8K
per month
- Global rank#1,671,085
among all websites
- Category rank#2,248
Health · Biotechnology and Pharmaceuticals
- Bounce rate38%
- Pages per visit2.1
- Average visit31 sec
- DevicesDesktop 36% · Mobile 64%
Websites whose visitors overlap most with AC Immune. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| addextherapeutics.com | 100% | 3.3K | #7,605,013 | View details | |
| biopharmadive.com | 83% | 680.7K | #208,628 | View details | |
ahccresearch.com | ahccresearch.com | 38% | – | – | – |
Top companies in Imaging Diagnostics
10 companies that operate in the same segment as AC Immune (Imaging Diagnostics), ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Handheld ultrasound devices are developed for whole-body medical imaging. | 2011 | Guilford, Connecticut, United States | USD 350 M | USD 97.61 M | 464 | |
Technology tools and systems for molecular scale are developed. | 1959 | Abingdon, Oxfordshire, United Kingdom | – | USD 648.1 M | – | |
MR-interfaced ultrasound devices for cancer and neurology treatments are provided. | 1999 | Tirat Carmel, Haifa District, Israel | USD 574.2 M | – | 541 | |
Robotic microsurgical systems for endoscopy are developed. | 2007 | Redwood City, California, United States | USD 733.62 M | – | 91 | |
Manufacturer of imaging and surgical products | 1919 | Tokyo, Tokyo, Japan | – | USD 6.49 B | 35,933 | |
Ultrasound images are analyzed via AI-based software provided by Exo. | 2015 | Redwood City, California, United States | USD 463.39 M | – | – | |
Planar X-ray radiology products for diagnostic imaging are supplied. | 2000 | Oxford, Oxfordshire, United Kingdom | USD 43.43 M | USD 1.04 M | 50 | |
Digital X-ray sources are developed by Nanox for cloud-based diagnostics. | 2004 | Jerusalem, Jerusalem District, Israel | USD 110.72 M | USD 13.02 M | 165 | |
ImaginAb is focused on developing advanced immuno-oncology imaging technologies. | 2007 | Los Angeles, California, United States | USD 59.64 M | – | – | |
Portable wireless ultrasound systems are developed for medical imaging. | 2014 | Burnaby, British Columbia, Canada | USD 21.87 M | – | – |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Ac Immune
Complete news archive for AC Immune
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about AC Immune
AC Immune was founded in 2003.
AC Immune is headquartered in Lausanne, Switzerland. It is registered at Lausanne, Vaud, Switzerland.
Andrea Pfeifer is the current CEO of AC Immune.
AC Immune is a funded company, having raised a total of $119.82M across 9 funding rounds to date. The company's 1st funding round was a Series A of $2.21M, raised on Jul 2003.
AC Immune has 172 employees.
Annual revenue of AC Immune is $4.3M as on Dec 31, 2025.
AC Immune was founded in 2003 in Lausanne, Switzerland, within the biotechnology sector. Focus is placed on developing antibodies, small molecules, and vaccines targeting Alzheimers disease, Parkinsons, Down syndrome, and glaucoma. A diversified pipeline is maintained, supported by technology platforms such as SupraAntigen for diagnostics and biologics, and Morphomer for small molecule drugs. Operations emphasize neurodegenerative disorders through research and therapeutic innovation.
AC Immune's top competitors include BeiGene, BioNTech and Decibel Therapeutics.
AC Immune offers Active Immunotherapies, Morphomer Platform, and Supraantigen Platform.
Yes, AC Immune is publicly traded on NASDAQ under the ticker symbol ACIU.
AC Immune has 5 investors. Key investors include Lilly, The Michael J. Fox Foundation, BVF Partners, Avidity Partners, and Redmile Group.
AC Immune operates through Ac Immune Sa.